Deficient Lmna in fibroblasts: an emerging role of non-cardiomyocytes in DCM

Xinjie Wang, Weijia Luo, Jiang Chang

Center for Genomic and Precision Medicine, Texas A&M University, Institute of Biosciences and Technology, Houston, TX 77030, USA.

Correspondence to: Prof. Jiang Chang, MD, Ph.D, Texas A&M University, Institute of Biosciences and Technology, 2121 W. Holcombe Blvd, Houston, TX 77030, USA. E-mail: jiangchang@tamu.edu

How to cite this article: Wang X, Luo W, Chang J. Deficient Lmna in fibroblasts: an emerging role of non-cardiomyocytes in DCM. J Cardiovasc Aging 2022;2:38. https://dx.doi.org/10.20517/jca.2022.26

Received: 1 Jul 2022 Accepted: 7 Jul 2022 Published: 8 Jul 2022

LMNA gene encodes intermediate filament proteins Lamin A/C. Lamin A and Lamin C polymerize to form nuclear lamina, mainly located in the inner layer of the nuclear envelope. As an essential component of the nuclear envelope, Lamins are necessary for nuclear structural integrity and participate in chromatin organization, cell cycle regulation, and DNA damage response[1]. By far, LMNA has the largest and most diverse number of disease-related mutations in the human genome[2]. More than 450 different mutations are linked to laminopathies among organs and tissues, including peripheral nerve (Charcot-Marie-Tooth neuropathy), adipose tissue (familial lipodystrophy), muscle tissue (muscular dystrophy, dilated cardiomyopathy, and arrhythmia), multiple systems with accelerating aging (Hutchinson-Gilford progeria syndrome)[3]. Most LMNA mutations affect the striated muscles; about 165 LMNA mutations have been associated with dilated cardiomyopathy (DCM)[4].

DCM is one of the most common causes of heart failure and sudden cardiac death in the aging population, characterized by ventricular dilation and systolic dysfunction. Notably, gene mutation contributes to approximately 40% of DCM causations, and more than 60 genes, including LMNA, have been identified as relevant to DCM. LMNA mutations lead to 5%-10% of DCM cases, with an age-related penetrance typically between 30 and 40[5]. 86% of LMNA mutation carriers exhibit cardiac phenotypes over 40, while 7% of the patients are younger than 20[4]. LMNA-related DCM usually presents conduction defect and ventricular
mutations, especially \( \beta \text{N195K/N195K} \) mice, related to the intolerance to energy deficits \( \alpha \) mice, remodeled connexin expression 40/43 on the lateral surface of 5 typical dysfunction, myocardial fibrosis, increased apoptosis, and premature death within six weeks, recapitulating The (in fibroblasts was deleted by crossing PDGF receptor-
that the deletion of Here, Dr. Marian and his team generated a fibroblast-specific  lineages, such as fibroblasts. Emerging evidence indicated that cardiac fibroblasts and fibrosis play a significant role in DCM pathogenesis. However, a knowledge gap remains on whether cardiac fibroblasts also participate in the occurrence of Lamin A/C null (Lmna\(^{-/-}\)) mice, cardiac-specific mutation Myh6-tTA:tetO-Lmna\(^{D300N}\) mice, and cardiac-specific knockout mice (Myh6-Cre:Lmna\(^{FF}\) mice\(^{7-9}\)). Interestingly, heterozygous lines with listed mutations grow normally at an early stage but progressively develop DCM at about 12 months. Another systemic mutation-introduced mouse line, Lmna\(^{H222P/H222P}\), exhibited DCM in adulthood, while heterozygous mice lived comparably to wild-type mice\(^{10}\). Transcriptomic analyses have provided clues to illustrate the pathogenic mechanisms. Abnormal activation of MAPK signaling (ERK1/2, JNK, and p38\(^{a}\)) and AKT/mTOR signaling has been found in Lmna\(^{H222P/H222P}\) mice, related to the intolerance to energy deficits and decompensation\(^{10}\). Upregulation of TGF-\( \beta \) signaling in the Lmna\(^{H222P/H222P}\) mouse heart accounts for the myocardial fibrosis. Genes involved in apoptosis, pro-inflammatory cytokines, DNA damage response, and senescence were upregulated upon the Lmma variant-driven activation of TP53 in Myh6-tTA:tetO-Lmna\(^{D300N}\) mice\(^{8}\). In Lmna\(^{N195K/N195K}\) mice, remodeled connexin expression 40/43 on the lateral surface of cardiomyocytes may impair the gap junction communications, while decreased expression of Hf1b/Sp4 in ventricles may affect the cardiac conduction system\(^{8}\).

In addition to in vivo models, patient-specific induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been developed as a new and popular model to mimic human diseases and provide the possibility of precision medicine. Patient-derived hiPSC-CMs carrying LMNA mutations, especially frameshift mutation, are superior models replicating different DCM-related arrhythmia phenotypes and give the opportunities to elucidate the Lamin regulated-calcium handlings mechanism. A patient-derived hiPSC-CMs carrying LMNA\(^{S143P}\), a prevalent mutation in Finland, have shown increased arrhythmia on \( \beta \)-adrenergic stimulation and are more sensitive to hypoxia\(^{11}\). Another patient-derived hiPSC-CMs with a frameshift mutation, K117fs, exhibit induced arrhythmias, dysregulation of CAMK2/RYR2 mediated-calcium homeostasis, and electrical abnormalities, consistent with the phenotypes in DCM patients\(^{12}\). The aberrant activation of platelet-derived growth factor (PDGF) receptor-\( \beta \) (PDGFRB) due to haploinsufficiency of Lamin A/C is considered to contribute to the arrhythmic phenotype in mutant hiPSC-CMs\(^{12}\).

To date, almost all mechanistic studies on LMNA-related DCM have focused on cardiomyocytes, as cardiomyopathy is considered the disease of cardiomyocytes. However, as mentioned at the beginning, LMNA is widely expressed. The gene carrying the casual mutations in CMs is also expressed in other cell lineages, such as fibroblasts. Emerging evidence indicated that cardiac fibroblasts and fibrosis play a significant role in DCM pathogenesis. However, a knowledge gap remains on whether cardiac fibroblasts also participate in the occurrence of LMNA-associated DCM.

Here, Dr. Marian and his team generated a fibroblast-specific Lmma knockout mouse line and demonstrated that the deletion of Lmma in cardiac fibroblasts contributes to senescence-related DCM phenotype\(^{13}\). Lmma in fibroblasts was deleted by crossing PDGF receptor-\( \alpha \) recombinase (Pdgfra-Cre) and floxed Lmma (Lmma\(^{F/F}\)) mice. Nearly 80% of Lmma was absent in cardiac fibroblasts, confirming the knockout efficiency. The Pdgfra-Cre:Lmma\(^{FF}\) mice showed growth retardation, cardiac conduction defects, arrhythmias, cardiac dysfunction, myocardial fibrosis, increased apoptosis, and premature death within six weeks, recapitulating typical Lmma-DCM phenotypes. Significantly smaller body weights and higher mortality observed in
Figure 1. Patient-related \textit{LMNA} mutant mouse models. Most animal models are generated based on \textit{Lmna} mutation or deletion in cardiomyocytes and have contributed to investigations on DCM pathogenesis. The current fibroblast-specific \textit{Lmna}-deficient mice demonstrated a similar DCM phenotype compared to cardiomyocyte \textit{Lmna}-deficient models, with the signature of growth retardation, arrhythmia, and myocardial fibrosis, and senescence-associated secretory phenotype. Mechanistic studies showed upregulation of TGF-\beta signaling, activation of DNA damage response and apoptosis, and cell senescence. Collectively, cardiac fibroblasts with \textit{Lmna} deficiency jointly contribute to DCM with cardiomyocytes. With this discovery, the non-cardiomyocytes are emerging as important new players in the pathogenesis of \textit{LMNA}-DCM. (Created with BioRender.com).

\textit{Pdgfra-Cre:Lmna}\textsuperscript{F/F} mice are similar to the phenotypes in mice with global or cardiac homozygous \textit{Lmna} deletion or mutations. Increased LVEDDI and LVMI and decreased LVFS in \textit{Pdgfra-Cre:Lmna}\textsuperscript{F/F} mice indicated left ventricular dilation and systolic dysfunction. Parallelly, cardiomyocyte hypertrophy was found in \textit{Lmna} fibroblast-knockout mice. 8/12 of the \textit{Pdgfra-Cre:Lmna}\textsuperscript{F/F} mice exhibited various arrhythmias. Interestingly, the heterozygous (\textit{Pdgfra-Cre:Lmna}\textsuperscript{W/F}) developed a similar but slowly progressing phenotype with disease onset at 12–18 months of age, correlating to an age-associated penetrance in patients and dosage-dependency of laminopathy. Moreover, increased collagen volume fraction combined with elevated TGF-\beta1 implied progressive myocardial fibrosis in \textit{Lmna}-deficient mouse hearts. Given that fibroblasts can crosstalk with cardiomyocytes via paracrine signals, extracellular matrix remodeling, and electric coupling, \textit{Lmna}-deficient fibroblasts may account for those cardiac phenotypes\cite{14}. Escalation of apoptosis was induced by \textit{Lmna} knockout in conjunction with activation of DNA damage response, likely due to the damaged structure of the nucleus envelope due to Lamin A/C deficiency. Noteworthily, a senescence-associated secretory phenotype (SASP) was discovered in fibroblast-specific \textit{Lmna}-deleted mice.
Incorporating with studies on cardiomyocytes, *Lmna* deletion in fibroblasts displayed a cohesive phenotype and similar pathogeneses, implying a potential synergetic mechanism between cardiac myocytes and fibroblasts.

In this paper, the authors elaborately defined the progressive DCM phenotype, thoroughly demonstrating the potential role of fibroblasts in *LMNA*-DCM, and proposed underlining mechanisms. These findings are remarkable as presenting the first direct evidence that fibroblasts participate in the *LMNA*-regulated DCM pathogenesis. The study provides a new angle on delineating the underlying mechanism for DCM with *LMNA* mutations. That is, non-cardiomyocytes such as cardiac fibroblasts, and cardiomyocytes, jointly contribute to DCM pathogenesis. This research and future investigations on the function of *LMNA* in endothelial and smooth muscle cells will further critical new information for clinical treatments.

A few limitations of the study are noted. As the authors mentioned in the discussion, *Pdgfra* is not a unique marker for cardiac fibroblasts. The *Pdgfra* promoter-driven Cre expression may lead to partial deletion of *LMNA* in other cell types and tissues, eventually affecting the net phenotype. To exclude the effect of non-cardiac-fibroblast *LMNA* deletion, the authors screened the comprehensive metabolic panel, which suggested no apparent abnormalities in liver or kidney, and electrolyte disturbances, except a reduced glucose level in plasma. Interestingly, around 25% of cardiomyocytes showed *LMNA* deletion in *Pdgfra-Cre:Lmna* mice. However, *Pdgfra-Cre:Lmna* mice with intact Lamin A/C expression in cardiomyocytes still developed DCM with a late-onset, implying a fibroblast-independent role in the disease progression. While the lack of highly specific markers for cardiac fibroblasts remains a challenge in the field, the inducible *Tcf21-MerCreMer* could serve as an alternative approach to confirm the fibroblast contribution to DCM. Additionally, *Lmna* can be ablated in active myofibroblasts by *Postn-MerCreMer* to further elucidate the role of fibroblast *LMNA* in other comorbid cardiovascular diseases such as myocardial infarction and diabetic cardiomyopathy.

In summary, the current study filled the knowledge deficiency of cardiac fibroblasts in developing *LMNA* deficiency-induced cardiomyopathy. The new information expands the understanding of the pathogenesis of the *LMNA*-induced DCM.

**DECLARATIONS**

**Authors’ contributions**

Conceptualization and writing: Wang X, Luo W, Chang J
Creating the graphical abstract and writing: Wang X, Luo W
Supervision: Chang J

**Availability of data and materials**

Not applicable.

**Financial support and sponsorship**

This work was supported by DOD PRMRP Discovery Award PR192609 (Weijia Luo) and American Heart Association-TPA 19T5803011, NHLBI R01 HL141215, NHLBI R01 HL150124, NHLBI R01 HL148133 and NHLBI R21 HL157708 (Jiang Chang).

**Conflicts of interest**

All authors declared that there are no conflicts of interest.
Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Dechat T, Adam SA, Taimen P, Shimi T, Goldman RD. Nuclear lamins. *Cold Spring Harb Perspect Biol* 2010;2:a000547. DOI PubMed
2. Burke B, Stewart CL. The nuclear lamins: flexibility in function. *Nat Rev Mol Cell Biol* 2013;14:13-24. DOI PubMed
3. Charron P, Arbustini E, Bonne G. What should the cardiologist know about lamin disease? *Arrhythm Electrophysiol Rev* 2012;1:22-8. DOI PubMed
4. Tesson F, Saj M, Uvaze MM, Nicolas H, Płoski R, Bilińska Z. Lamin A/C mutations in dilated cardiomyopathy. *Cardiol J* 2014;21:331-42. DOI PubMed
5. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. *Nat Rev Cardiol* 2013;10:531-47. DOI PubMed
6. Brodt C, Siegfried JD, Hofmeyer M, et al. Temporal relationship of conduction system disease and ventricular dysfunction in LMNA cardiomyopathy. *J Card Fail* 2013;19:233-9. DOI PubMed PMC
7. Kubbén N, Voncken JW, Konings G, et al. Post-natal myogenic and adipogenic developmental defects and metabolic impairment upon loss of A-type lamins. *Nucleus* 2011;2:195-207. DOI PubMed PMC
8. Mounkes LC, Kozlov SV, Rottman JN, Stewart CL. Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. *Hum Mol Genet* 2005;14:2167-80. DOI PubMed
9. Chen SN, Lombardi R, Karmouch J, et al. DNA Damage response/TP53 pathway is activated and contributes to the pathogenesis of dilated cardiomyopathy associated with LMNA (Lamin A/C) mutations. *Circ Res* 2019;124:856-73. DOI PubMed PMC
10. Arimura T, Helbling-Leclerc A, Massart C, et al. Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. *Hum Mol Genet* 2005;14:155-69. DOI PubMed
11. Shah D, Virtanen L, Prajapati C, et al. Modeling of LMNA-related dilated cardiomyopathy using human induced pluripotent stem cells. *Cells* 2019;8:594. DOI PubMed PMC
12. Lee J, Termglinchan V, Diecke S, et al. Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy. *Nature* 2019;572:335-40. DOI PubMed PMC
13. Rouhi L, Auguste G, Zhou Q, et al. Deletion of the Lmna gene in fibroblasts causes senescence-associated dilated cardiomyopathy by activating the double-stranded DNA damage response and induction of senescence-associated secretory phenotype. *J Cardiovasc Aging* 2022;2:14. DOI
14. Nicin L, Wagner JUG, Luxáén G, Dimmeler S. Fibroblast-mediated intercellular crosstalk in the healthy and diseased heart. *FEBS Lett* 2022;596:638-54. DOI PubMed
15. Acharya A, Baek ST, Banfi S, Eskiozak B, Tallquist MD. Efficient inducible Cre-mediated recombination in Tcf21 cell lineages in the heart and kidney. *Genesis* 2011;49:870-7. DOI PubMed PMC
16. Kanisicak O, Khalil H, Ivey MJ, et al. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. *Nat Commun* 2016;7:12260. DOI PubMed PMC
17. Levick SP, Widipradja A. The diabetic cardiac fibroblast: mechanisms underlying phenotype and function. *Int J Mol Sci* 2020;21:970. DOI PubMed PMC